Despite its high prevalence, few pharmacological treatments outside antihistamines and melatonin exist for sleep disorders among pediatric populations (Chevreuil et al. 2010). Few clinical trials have examined whether benzodiazepines, such as Zolpidem, may benefit autistic spectrum disorder (ASD) children with sleep disorders (Chevreuil et al. 2010). A recent case report suggests Zolpidem was effective in reducing catatonic behavior in an adolescent with ASD (Zaw and Bates 1997). However, murine models suggest zolpidem exacerbates social and cognitive deficits observed in ASD children (Banerjee et al. 2012; Han et al. 2014). Further clinical trials are required to elucidate the mechanism, therapeutic use, and side effects of Zolpidem among ASD children with sleep disorders.
References and Reading
- Banerjee, A., García-Oscos, F., Roychowdhury, S., Galindo, L. C., Hall, S., Kilgard, M. P., & Atzori, M. (2012). Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. The International Journal of Neuropsychopharmacology, 16(06), 1309–1318. https://doi.org/10.1017/s1461145712001216.CrossRefPubMedPubMedCentralGoogle Scholar
- Han, S., Tai, C., Jones, C. J., Scheuer, T., & Catterall, W. A. (2014). Enhancement of inhibitory neurotransmission by GABA A receptors having α 2,3 -subunits Ameliorates behavioral deficits in a mouse model of autism. Neuron, 81(6), 1282–1289. https://doi.org/10.1016/j.neuron.2014.01.016.CrossRefPubMedPubMedCentralGoogle Scholar